November 20 marks World Chronic Obstructive Pulmonary Disease (COPD) Day—a global initiative highlighting the critical importance of lung function assessment. This year’s theme, “Know Your Lung Function,” underscores that spirometry remains the gold standard for diagnosing COPD. While smoking is the leading modifiable risk factor, emerging evidence confirms that lung development continues from fetal life through adolescence and into early adulthood—making this entire period a window of vulnerability. Exposure to ambient air pollution, recurrent respiratory infections, occupational dusts and chemicals, and indoor pollutants—including biomass fuel used for cooking and heating—can impair lung growth trajectories and predispose individuals to chronic respiratory disease later in life. Alarmingly, up to 50% of lung function may be lost before patients develop noticeable symptoms. Crucially, lung function is not merely a marker of pulmonary health; it serves as a robust predictor of overall morbidity, cardiovascular risk, and all-cause mortality.
COPD is a progressive, heterogeneous disorder characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities—most commonly manifesting as chronic bronchitis and/or emphysema. Early recognition is vital: hallmark symptoms include chronic cough, sputum production, exertional dyspnea, and declining exercise tolerance. Initially, breathlessness may occur only during strenuous activity; however, as disease advances, even basic tasks such as dressing or climbing stairs become increasingly challenging.
Diagnosis hinges on clinical evaluation supported by objective testing. Spirometry—specifically the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC)—is indispensable. A post-bronchodilator FEV1/FVC ratio < 0.70 confirms persistent airflow obstruction. Chest radiography or high-resolution CT may be employed to assess structural changes and rule out alternative diagnoses such as bronchiectasis or interstitial lung disease.
Management follows a comprehensive, individualized strategy aimed at symptom control, reducing exacerbation frequency and severity, improving functional status, and prolonging survival. First-line pharmacotherapy includes long-acting bronchodilators—beta2-agonists (LABAs) and muscarinic antagonists (LAMAs)—often combined with inhaled corticosteroids in patients with frequent exacerbations or elevated blood eosinophil counts. Smoking cessation remains the single most effective intervention to slow disease progression. Pulmonary rehabilitation—incorporating supervised exercise training, nutritional counseling, and psychosocial support—is strongly recommended for all symptomatic patients with impaired functional capacity. Long-term oxygen therapy is indicated for those with severe resting hypoxemia (PaO2 ≤ 55 mmHg or SpO2 ≤ 88%).
Nutritional optimization plays a pivotal role in COPD management. Increased ventilatory demand elevates caloric and protein requirements, placing patients at high risk for cachexia and muscle wasting. Dietary plans should prioritize adequate energy intake, high-quality protein, and micronutrient sufficiency—delivered via frequent, smaller meals to minimize dyspnea-inducing gastric distension. Foods that promote gas formation (e.g., carbonated beverages, legumes, cruciferous vegetables) or constipation (e.g., fried foods, dried fruits, nuts) should be moderated. While traditional Chinese medicine concepts such as “lung-kidney deficiency” inform complementary approaches, evidence-based integrative care emphasizes dietary patterns rich in antioxidants and anti-inflammatory compounds—such as those found in whole grains, berries, leafy greens, and omega-3 fatty acids—rather than unvalidated herbal formulations.
Prevention begins with primary interventions: tobacco control, improved household ventilation, regulation of occupational exposures, and reduction of ambient air pollution. For diagnosed patients, adherence to maintenance therapy, annual influenza and pneumococcal vaccination, and regular spirometric monitoring are cornerstones of self-management. As COPD affects over 390 million people worldwide—and remains the third leading cause of death globally—raising awareness, expanding access to spirometry, and integrating multidisciplinary care are essential steps toward mitigating its profound personal, familial, and socioeconomic burden.